As an efficacious treatment for the HIV virus, the NRTI Lamivudine is now showing promise as a drug to combat age-related macular degeneration, known also as AMD. Nucleoside reverse transcriptase inhibitors, or NRTIs are the most commonly used class of anti-HIV medications and they are touted to successfully act on the enzyme reverse transcriptase, prohibiting[…]
NRTI Lamivudine Looks Promising for AMD Treatment
Anti-Retroviral / Anti-HIV, Drug Research & Development API Tags: AMDHIV virus Jan 05, 2015
Winning the Fight Against AIDS One Drug at a Time
Anti-Retroviral / Anti-HIV, Antiviral, Drug Research & Development API Tags: antiretroviral therapyHIV virus Dec 02, 2014
December 1, 2014 marked World AIDS Day, with roughly 40 million deaths worldwide over the past three decades attributed to this virulent disease. While there is no known cure for AIDS the advent of multiple drug regimens has made the treatment of the HIV virus which causes AIDS manageable for many patients globally. Unfortunately there[…]
Pyrazinamide is a Triple Threat to TB in HIV Patients
Anti-Retroviral / Anti-HIV, Antibacterial, Antibiotic, Drug Research & Development API Tags: HIV infectionHIV virus Aug 08, 2014
Midstage trial data of a Pyrazinamide cocktail to treat TB has offered encouraging news for patients with the HIV infection. Coined PaMZ, this drug trio includes Pyrazinamide and two antibacterial drugs, with results going into the Phase III trial looking promising. The antibacterial drugs are PA-824, which was initially developed by the Novartis and the[…]
Cidofovir Shortage Affects HIV Positive Patients with Cytomegalovirus Retinitis
Anti-Retroviral / Anti-HIV, Antiviral, Drug Research & Development API, FDA Drug Shortage Tags: HIV virus Nov 06, 2013
As an antiviral medication used to treat cytomegalovirus retinitis, also known as CMV in patients infected with the HIV virus, the current Cidofovir shortage is alarming (see the FDA Cidofovir shortage posting). Administered as an injectable treatment intravenously, the dosing of Cidofovir can take up to six hours to complete. The treatment of 75 mg/ml[…]
Dolutegravir Approved by the FDA as an Effectual Integrase Inhibitor
Anti-Retroviral / Anti-HIV Tags: AIDSHIV infectionHIV virus Aug 26, 2013
On August 12, 2013 Viiv Healthcare proudly announced the FDA approval of the integrase inhibitor, Dolutegravir to combat the HIV virus. Known as the brand name Tivicay, Dolutegravir is typically used in combination with other antiretroviral medications to treat patients with AIDS, ages twelve and older. With many patients living longer while being infected with[…]
Etravirine Remains a Formidable Treatment for AIDS
Anti-Retroviral / Anti-HIV, Antiviral, Drug Research & Development API, FDA Approved 2012, Patent Expiration 2019 Tags: AIDSHIV virus Jul 01, 2013
As a successful nonnucleoside reverse transcriptase inhibitor, Etravirine, CAS number 269055-15-4 is also known as the brand name Intelence. With the patent for Intelence set to expire for Janssen on November 5, 2019, additional research and development offering generic formulations of this effectual treatment for AIDS is sure to proliferate. Last year Etravirine was approved[…]
New Tenofovir Pro-Drug Offers Less Toxicity
Anti-Retroviral / Anti-HIV, Drug Research & Development API, Patent Expiration 2017 Tags: HIVHIV infectionHIV virus Mar 25, 2013
On March 6, 2013 The Physician’s Weekly reported that a new Tenofovir Pro-Drug had less potential for bone and kidney toxicity, but still remained efficacious as a treatment for both Hepatitis and HIV infection. The findings were revealed at the 20th Conference on Retroviruses and Opportunistic Infections 2013 in Atlanta, Georgia. Tenofovir is a vastly[…]
Can Ritonavir Boosted Fosamprenavir Lead to a Cure for AIDS?
Anti-Retroviral / Anti-HIV, Drug Research & Development API, Patent Expiration 2017 Tags: AIDSHIV virusNorvirRitonavir Mar 07, 2013
The recent headlines proclaiming a cure for a Mississippi baby who had been exposed to the HIV virus which causes AIDS have captivated the world. This child was born to an HIV positive mother who had not received any prenatal care to reduce the transmission of the virus. Dr. Hannah Gay, who treated the baby,[…]
Lamivudine Is Still a Formidable Treatment for HIV and HBV
Anti-Retroviral / Anti-HIV, Antiviral, Patent Expiration 2016 Tags: antiretroviral therapychronic hepatitis BHIV virus Nov 12, 2012
Lamivudine is also known as Epvir. Marketed by GlaxoSmithKline, the patent for Epvir is due to expire on May 18, 2016. Lamivudine is an antiviral medication that prevents human immunodeficiency virus (HIV) or hepatitis B (HBV) virus cells from multiplying in the body. This medication will treat HIV and HBV, but it is not a[…]
Monotherapy with Darunavir is Where the "MONET" is
Anti-Retroviral / Anti-HIV, Drug Research & Development API Tags: AIDSDarunavir EthanolateHIVHIV virusRitonavir Sep 02, 2011
AIDS is a global pandemic whose cure has eluded scientists and doctors for more than 2 decades. Acquired immunodeficiency syndrome (AIDS) is caused by the Human Immunodeficiency Virus (HIV) which progressively undermines the strength of the immune system until such a time that the body becomes incapable of fighting off infections and vulnerable to opportunistic[…]